BPI 15086

Drug Profile

BPI 15086

Alternative Names: BPI15086

Latest Information Update: 27 Apr 2017

Price : $50

At a glance

  • Originator Betta Pharmaceuticals Co Ltd
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 01 Oct 2016 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT02914990)
  • 22 Sep 2016 Betta Pharmaceuticals plans a phase I trial for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in China (NCT02914990)
  • 01 Sep 2016 Preclinical trials in Non-small cell lung cancer in China (PO) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top